definiens: has the meaning ascribed to it in Section 8.1 . of this Agreement ; ( j ) means the date upon which CORIXA or a CORIXA 's Affiliates shall have delivered t o PMC or an Authorized PMC Affiliate that PMC shall designate, quantities of Material meeting Material Specifications as described in Schedule C hereto sufficient to enable PMC and its Affiliates to implement the Evaluation Plans during the Option Period a nd to evaluate PMC 's interest in exercising the Option ; ( jj ) has the meaning ascribed to it in Article 16 of this Agreement ; ( k ) means the evaluation plans established by PMC and agreed to and accepted by CORIXA with respect to each Field of Use which describe evaluation works that shall be performed by PMC in each Field of Use during the Option Period, and which are attached hereto as Exhibit 2 ; ( l ) means the use of LeIF as an adjuvant in [ * * * ] vaccines for [ * * * ] immunization ( [ * * * ] ) against the following infectious diseases : ( i ) Influenza, ( ii ) Acquired Immunodeficiency Syndrome ( ), ( iii ) Malaria, ( vi ) Resp iratory Syncitial Virus ( ) and ( v ) Mycobacterium Tuberculosis ; and ( singular ) means any one of the foregoing, and further provided that the [ * * * ] ; ( m ) means, in each country of the Territory, t he first commercial sale of a Product by PMC, its Affiliates or Sublicensees to a Third -Party following, if required by law, approval of its marketing and its pricing by the appropriate governmental agency for the country in which the sale is to be made an d, when such approval is not required by -3- 4 law, the first commercial sale in that country, in each case for use or consumption of such Product in such country by the general public ; for avoidance of doubt, F irst Commercial Sale of a given Product can not occur more than once in any particular country of the Territory ; ( n ) has the meaning ascribed to it in Section 9.2.2 hereof ; ( mm ) shall have the meaning assigned to it in Section 9.2.2 hereof ; ( n ) has the meaning ascribed to it in Section 2.3.1 . of this Agreement ; ( nn ) means any and all technical information, processes, formulae, data, engineering, technical and shop drawings, inventions, shop -rights, chemical compounds, know -how and trade secrets, in each case that is Confidential Information according to Article 8, that is useful or necessary to make, have made, use or sell Products or to practice under the Licensed Patents and/or the Joint Research Patents in the Field of Use, which have been, or hereafter are, either developed by CORIXA or its Affiliates, or the rig hts to which in the Field of Use have been acquired by CORIXA or its Affiliates . In particular, but without prejudice to the generality of the foregoing, Licensed Know -How shall include, with respect to Material, chemical and analytical methods and data, M aterial specifications, pharmacological and toxicological methods and data ; ( o ) means : ( i ) any existing patents and patent applications isted in Schedule A to this Agreement ; ( ii ) any future patents issued from any patent applications referred to in Paragraph 1.1.(o).(i ) above and any future patents issued from a patent application filed in any country in the Territory which corresponds to a patent o r patent application identified in Paragraph 1.1.(o).(i ) above ; ( iii ) any future patent issued, assigned or licensed to CORIXA or its Affiliates or to any employee, contractor, subcontractor or agent of the foregoing from a paten t application filed in any country, useful or necessary to make, have made, use or sell Products or to make, have made or use Material ; ( iv ) any reissues, confirmations, renewals, extensions ( including but not limited to extens ions referred to in Article 11 hereof ), counterparts, divisions or continuations issued, assigned or licensed to CORIXA or its Affiliates of or relating to the patents or patent applications identified in Paragraph 1.1.(o).(i ), ( ii ) and ( iii ) above ; and -4- 5 ( v ) any continuations -in - part or patent -of - addition issued, assigned or licensed to CORIXA or its Affiliates and of or relating to the patents or patent applications identified in Paragraph 1.1.(o).(i ), ( ii ) or ( iii ) hereof ; ( vi ) any CORIXA Research Patents and CORIXA 's interest in Joint Research Patents ; For greater certainty, whenever used, include the invention s disclosed in and the subject matter of patent applications ; ( p ) means the Special Material Transfer Agreement attached hereto as Exhibit 1 ; ( q ) means the gross amount received by PMC, its Affiliate s and Sublicensees from the sale or other disposition of Products to Third -Parties, less the sum of the following deductions for amounts actually incurred related to said sale or other disposition : ( i ) normal, customary trade d iscounts ( including volume discounts ), credits and rebates and allowances and adjustments for rejections, recalls and returns ; ( ii ) cost of freight and insurance, sales, use, excise, value -added and similar taxes and duties i mposed on the sale and included in the gross amount charged to customers, and government -mandated vaccine insurance premium ; ( r ) has the meaning ascribed to it in Section 19.3.(a ) of this Agreement ; ( s ) is defined in Section 2.2.4 . hereof ; ( t ) means, with respect to the Fields of Use, the option granted by CORIXA to PMC pursuant to the provisions of Section 2.2